A new blood test may help predict early-stage breast cancer patients at highest risk for recurrence
Full article:

Which patients are at risk for a relapse of early-stage breast cancer? Tests to predict recurrence would help find people who need more monitoring after treatment and provide a chance to find and treat them earlier. This study looked at whether a blood test for tumor DNA (called circulating tumor DNA or ctDNA) is useful for finding people with recurrence earlier than current clinical practice. (11/4/19)

Este artículo está disponible en español.

Questions To Ask Your Health Care Provider

Open Clinical Trials

The following research studies are looking at liquid biopsy and cancer. 

Visit our Featured Research Page and Research Search and Enroll Tool to find additional studies enrolling people with, or at high risk for cancer. 


FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.